What is Standard BioTools Inc. (LAB)?

Standard BioTools Inc. (LAB) is a stock in the Healthcare sector, Medical - Specialties industry. View full analysis on Stocks360.

What is the current price of LAB?

The current price of LAB is $0.62. Prices are updated in real time on Stocks360.

What is LAB's price-to-earnings (PE) ratio?

LAB's trailing twelve-month PE ratio is -2.67, based on current price and earnings per share data available on Stocks360.

What is LAB's market capitalization?

LAB's market capitalization is $241,867,814.00, placing it in the small-cap tier.

Standard BioTools Inc. (LAB)

Stock analysis · NASDAQ · Healthcare · Medical - Specialties

$0.62

Market Cap

$241.87M

PE (TTM)

-2.67

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.35

Day Range

$0.59 – $0.63

52-wk Range

$0.59 – $1.72

Avg Volume

N/A

Volume

1.04M

Standard BioTools Inc. (LAB) is a publicly traded company in the Healthcare sector. Latest price: $0.62. Market cap $241.87M. Trailing PE -2.67. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $1.27 2026-10-27 · $0.62 (-51.49%)

Earnings

Most Recent

Aug 5, 2026

EPS $-0.07 vs est. $-0.01

Missed by $0.06

Next Earnings

Nov 3, 2026

EPS estimate $-0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Standard BioTools Inc.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic researc…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.67×
P/S (TTM)	2.86×
P/B	0.45×
P/FCF (TTM)	-2.93×
EV / EBITDA	0.00×
EV / Sales	-0.00×
Earnings Yield	-36.29%
Free Cash Flow Yield	-34.14%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$71.19K
Net Income (TTM)	-$87.76M
Free Cash Flow (TTM)	-$82.57M
Net Debt	-$241.94M
Working Capital	$460.06M
Gross Margin	49.14%
Operating Margin	-94.80%
Net Margin	-103.29%
Return on Equity	-18.16%
Return on Invested Capital	-8.25%